
Hyderabad, the new vaccine capital of India
Apart from Covaxin and Sputnik V, companies based in the city are also involved in developing or manufacturing several other Covid-19 vaccines.
Apart from Covaxin and Sputnik V, companies based in the city are also involved in developing or manufacturing several other Covid-19 vaccines.
While the government rolled out the Covid-19 vaccination programme on January 16, questions of accessibility and affordability remain for sections of the population.
The massive campaign to deploy the Covid-19 vaccine rests on infrastructure, both physical and digital. Using past campaigns, India put together a multi-pronged strategy for a smooth roll-out.
For BBIL’s founder Krishna Ella, the roll-out of a made-in-India vaccine, Covaxin, is peppered with challenges. Two recent deals with Brazilian and American firms have now buoyed him.